Quinolones: structure-activity relationships and future predictions

References

1. Lesher G. Y., Froelich E. D., Gruet M. D., Bailey J. H., Brundage R. P. 1,8 Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962; 5:1063–1068
   [Google Scholar]
2. Norris S., Mandell G. L. The quinolones: history and overview. In Andriole V. T. (ed) The quinolones London: Academic Press; 19881–22
   [Google Scholar]
3. Koga H., Itoh A., Murayama S., Suzue S., Irikura T. Structure– activity relationships of antibacterial 6, 7- and 7, 8-disubstituted 1-alkyl-1, 4-dihydro-4-oxoquinolone-3-carboxylic acids. J Med Chem 1980; 23:1358–1363
   [Google Scholar]
4. Mitscher L. A., Devasthale P., Zavod R. Structure–activity relationships. In Hooper D. C., Wolfson J. S. (eds) Quinolone antimicrobial agents Washington DC: American Society for Microbiology; 2nd edn 19933–51
   [Google Scholar]
5. Domagala J. M. Structure–activity and structure–side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33:685–706
   [Google Scholar]
6. Sanchez J. P., Domagala J. M., Hagen S. E. Quinolone antibacterial agents. Synthesis and structure–activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J Med Chem 1988; 31:983–991
   [Google Scholar]
7. Ball A. P., Tillotson G. S. Tolerability of fluoroquinolones antibiotics: past, present and future. Drug Safety 1995; 13:343–358
   [Google Scholar]
8. Remuzon P., Bouzard D., Guiol C., Jacquet J. P. Fluoronaphthyridines as antibacterial agents. 6. Synthesis and structure-activity relationships of new chiral 7-(l-, 3-, 4-, and 6-methyl-2,5-diazabicyclo [2.2.1] heptan-2-yl) naphthyridine analogues of 7-[(IR, 4R)-2,5-diazobicyclo [2.2.1.] heptan-2-yl)-l-(1,1-diamethylethyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid. Influence of the configuration of blood pressure in dogs. A quinolone-class effect. J Med Chem 1992; 35:2898–2909
   [Google Scholar]
9. Janknegt R., Hekster Y. A. Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives. Pharm Weeklbl [Sci] 1989; 11:33–43
   [Google Scholar]
10. Ingham B., Brentnall D. W., Dale E. A., MacFadzean J. A. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 1:21–26
    [Google Scholar]
11. Schaad U. B., Salam M. A., Aujard Y. Use of fluoroquinolones in paediatrics: concensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995; 14:1–9
    [Google Scholar]
12. Paton D. H., Reeves D. S. Adverse reactions to fluoroquinolones. Adv Drug React Bull 1992; 153:575–578
    [Google Scholar]
13. Sesnie J. C., Heifetz C. L., Joanides E. T., Malta T. E., Shapiro M. A. Comparative phototoxicities of quinolones in a mouse photo-tolerance model. In Proceedings of the 30th International Conference on Antimicrobial Agents and Chemotherapy Washington DC: American Society for Microbiology; 1990 abstract 399
    [Google Scholar]
14. Food and Drug Administration Anti Infectives Drugs Advisory Committee Review of phototoxicity issue with lomefloxacin and other fluoroquinolones. In Proceedings of the 46th Meeting of the Drugs Advisory Committee Washington DC: Food and Drug Administration; 1994
    [Google Scholar]
15. Ministry of Health and Welfare Pharmaceutical Affairs Dept Sparfloxacin and photosensitivity. In Information on Adverse Reactions to Drugs No. 127 Tokyo: Ministry of Health and Welfare; 19942–8
    [Google Scholar]
16. Bouchery D. Eviter toute activite a rexterieur. Paris: National Board of Pharmacovigilance, Information Medecin; 1995
    [Google Scholar]
17. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990; 26: Suppl D 7–29
    [Google Scholar]
18. Chin N. X., Chu D., Huang H. B., Neu H. C. A-86719.1, a new class DNA gyrase inhibitor, its time-killing activity, postantibiotic effect and assay condition effect. In Proceedings of the 34th International Conference on Antimicrobial Agents and Chemotherapy Washington DC: American Society for Microbiology; 1994 abstract F51
    [Google Scholar]
19. Alder J. P., Meulbroek J. M., Shipkowitz N. L. Efficacy of A-86719.1, a novel 2-pyridone gyrase inhibitor, for treatment of systemic, lung and abscess infections in mice and rats. In Proceedings of the 34th International Conference on Anti-microbial Agents and Chemotherapy Washington DC: American Society for Microbiology; 1994 abstract F53
    [Google Scholar]